Shared decision-making for non-operative management versus operative management of hip fractures in selected frail older adults with a limited life expectancy: a protocol for a nationwide implementation study

Autor: Suzanne Polinder, Detlef van der Velde, Taco Gosens, Esther M M van Lieshout, Michael H J Verhofstad, Pieter Joosse, K de Vries, Dennis Den Hartog, J. Jansen, Ruth E Pel-Littel, Henk Jan Schuijt, Miliaan L Zeelenberg, Paulieke C Oosterwijk, Hanna C Willems, Sverre A I Loggers, Thomas MP Nijdam, Hugo H Wijnen, E. Sohl, J.A. Jansen, M. Leijnen, W.A.H. Van der Stappen, M Peters-Kop, A.H. Van der Veen, N.C. Schepel, J.A.M. Wilmer, J. Steens, J. Winkelhagen, N.M.F. Noorda, H.A.A.M. Maas, O. Wijers, V. Vis, D. Van der Stap, G.R. Roukema, E. Bosma, T.M. Van Raaij, A.M. Van der Knaap, R. De Groot, A.V.C.M. Zeegers, H.A. Formijne Jonkers, D.H.R. Kempen, A.F Pull ter Gunne, M.P. Somford, E. Tanis, J.H. Duits, R.A. Zandbergen, N.C. Leegwater, O.C. Geraghty, J.H. Hegeman, E.M. Regtuijt

Publikováno v: BMJ Open, Vol 14, Iss 4 (2024)

Background and purpose Recent research has highlighted non-operative management (NOM) as a viable alternative for frail older adults with hip fractures in the final phase of life. This study aims to guide Dutch physicians and hospitals nationwide in

Externí odkaz: https://doaj.org/article/3edb7ca2aba14272bf955bbb67838815

Combination of sunitinib and 177Lu-labeled antibody cG250 targeted radioimmunotherapy: A promising new therapeutic strategy for patients with advanced renal cell cancer

Autor: Jeannette C. Oosterwijk-Wakka, Mirjam C.A. de Weijert, Gerben M. Franssen, Dimitar R. Kolev, Ton A.F.J. de Haan, Otto C. Boerman, Peter F.A. Mulders, Egbert Oosterwijk

Publikováno v: Neoplasia: An International Journal for Oncology Research, Vol 32, Iss , Pp 100826- (2022)

Sunitinib is an effective treatment for patients with metastatic Renal Cell Carcinoma (mRCC) but ultimately resistance occurs. The aim of this study was to investigate sunitinib resistance in RCCs and to develop therapeutic combination strategies wit

Externí odkaz: https://doaj.org/article/a3206bae57544db090053ce0eb8b6ee7

Supplementary Figure 1, Tables 1-2 from Differences in Natural History between Breast Cancers in BRCA1 and BRCA2 Mutation Carriers and Effects of MRI Screening-MRISC, MARIBS, and Canadian Studies Combined

Autor: Harry J. de Koning, Martin O. Leach, Don B. Plewes, Jan G.M. Klijn, Emiel J.T. Rutgers, Maartje J. Hooning, Jan C. Oosterwijk, Elisabeth Bergers, Martin N.J.M. Wasser, Nicoline Hoogerbrugge, Kimberly A. Hill, Ruth M.L. Warren, Elizabeth A. Ramsay, Gerrit Draisma, Reinie Kaas, Rosalind A. Eeles, Petrina A. Causer, Gareth Evans, Madeleine M.A. Tilanus-Linthorst, Fiona J. Gilbert, Ellen Warner, Eveline A.M. Heijnsdijk

PDF file - 99K, Transitions in the MISCAN model. From each pre-clinical stage, a tumor may be clinically diagnosed or may grow into the next pre-clinical stage. By applying screening, the tumor may be detected by screening.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c2cccabe22f89368c8fdfd1dd09f710
https://doi.org/10.1158/1055-9965.22437189

Data from Variation in Mutation Spectrum Partly Explains Regional Differences in the Breast Cancer Risk of Female BRCA Mutation Carriers in the Netherlands

Autor: Geertruida H. de Bock, Jan C. Oosterwijk, Liesbeth Jansen, Annemarie H. van der Hout, Richard M. Brohet, Hans F. Vasen, Encarna B. Gómez-Garcia, Hanne E.J. Meijers-Heijboer, Theo A.M. van Os, Margreet G.E.M. Ausems, Arjen R. Mensenkamp, Christi J. van Asperen, Margriet Collée, Flora E. van Leeuwen, Matti A. Rookus, Marian J.E. Mourits, Dorina M. van der Kolk, Natalia Teixeira, Janet R. Vos

Background: We aimed to quantify previously observed relatively high cancer risks in BRCA2 mutation carriers (BRCA2 carriers) older than 60 in the Northern Netherlands, and to analyze whether these could be explained by mutation spectrum or populatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ee2fb7a1642cf211acd7fd8abc807b8
https://doi.org/10.1158/1055-9965.c.6514963

PRDM10 directs FLCN expression in a novel disorder overlapping with Birt-Hogg-Dubé syndrome and familial lipomatosis

Autor: Irma van de Beek, Iris E Glykofridis, Jan C Oosterwijk, Peter C van den Akker, Gilles F H Diercks, Maria C Bolling, Quinten Waisfisz, Arjen R Mensenkamp, Jesper A Balk, Rob Zwart, Alex V Postma, Hanne E J Meijers-Heijboer, R Jeroen A van Moorselaar, Rob M F Wolthuis, Arjan C Houweling

Publikováno v: van de Beek, I, Glykofridis, I E, Oosterwijk, J C, van den Akker, P C, Diercks, G F H, Bolling, M C, Waisfisz, Q, Mensenkamp, A R, Balk, J A, Zwart, R, Postma, A V, Meijers-Heijboer, H E J, van Moorselaar, R J A, Wolthuis, R M F & Houweling, A C 2023, ' PRDM10 directs FLCN expression in a novel disorder overlapping with Birt-Hogg-Dubé syndrome and familial lipomatosis ', Human Molecular Genetics, vol. 32, no. 7, pp. 1223-1235 . https://doi.org/10.1093/hmg/ddac288
Human Molecular Genetics, 32, 1223-1235
Human Molecular Genetics, 32(7), 1223-1235. Oxford University Press
Human molecular genetics, 32(7), 1223-1235. Oxford University Press
Human Molecular Genetics, 32, 7, pp. 1223-1235

Contains fulltext : 291515.pdf (Publisher’s version ) (Open Access) Birt-Hogg-Dubé syndrome (BHD) is an autosomal dominant disorder characterized by fibrofolliculomas, pulmonary cysts, pneumothoraces and renal cell carcinomas. Here, we reveal a no

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19bee29415900ea2982a28cc3469f7db
https://research.vumc.nl/en/publications/d755d70a-4c1f-4979-ab6b-f902c4942091